PeproMene Bio's PMB-CT01 Achieves Full Remission in First B-ALL Patient

In a significant breakthrough, a patient suffering from relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has achieved complete remission following treatment with PMB-CT01, a novel BAFFR-CAR T Cell therapy developed by PeproMene Bio, Inc. This clinical-stage biotechnology company, based in Irvine, California, is dedicated to pioneering innovative treatments for cancer and immune disorders.

The patient, who was part of the first cohort in the Phase 1 clinical trial, reached complete remission just one month after receiving the treatment. This achievement follows the successful outcomes presented at the American Society of Hematology annual meeting, where the PMB-CT01 trial for relapsed/refractory non-Hodgkin's lymphoma resulted in durable complete remissions with minimal toxicity for all three patients involved.

The treatment was administered at City of Hope, a renowned institution in the United States for cancer research and treatment, and also the birthplace of the groundbreaking therapy. Throughout the initial phase of the treatment, the patient exhibited only mild side effects, including a low-grade cytokine release syndrome that resolved on its own, and no signs of immune effector cell-associated neurotoxicity syndrome.

The patient's previous treatments with chemotherapy and blinatumomab had failed, and his disease was identified as both CD19- and CD22-negative, leaving him with very few therapeutic options. However, the BAFFR-CAR T Cell treatment was well-tolerated, with the patient experiencing only minor and expected toxicities. The complete remission and the clearance of minimal residual disease (MRD) signify an outstanding response to this new therapeutic approach.

PeproMene's milestone in the development of PMB-CT01 is further validated by the preclinical research data from City of Hope, published in Science Translational Medicine in 2019. The study demonstrated that BAFFR-CAR T Cells are capable of effectively eliminating various B-cell malignancies, including B-ALL and different subtypes of B-lymphomas.

PMB-CT01 is a first-in-class therapy that targets the BAFF-R receptor, which is predominantly expressed on B cells and plays a crucial role in their proliferation and survival. The therapy is constructed using anti-BAFF-R antibodies with second-generation signaling domains, making it a promising treatment for B-cell malignancies.

PeproMene's lead candidate, PMB-CT01, is currently under investigation in Phase 1 clinical trials for the treatment of r/r B-ALL and B-cell Non-Hodgkin's lymphoma. The company is also advancing the development of BAFFR Bispecific T Cell Engager and BAFFR-CAR NK cells, showcasing its commitment to transforming cancer treatment through innovation.